Health Canada advisory impacts on the prevalence of oral codeine use in the Pediatric Canadian population: comparative study across provinces.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
04 Mar 2024
04 Mar 2024
Historique:
received:
21
06
2023
accepted:
27
02
2024
medline:
5
3
2024
pubmed:
5
3
2024
entrez:
4
3
2024
Statut:
epublish
Résumé
Health Canada (HC) has, since 2013, issued safety alerts restricting the use of codeine-containing drugs among breastfeeding women and children/adolescents under 18 years of age. These products are linked to breathing problems among ultra-rapid CYP2D6 metabolizers and early use of opioid can lead to future opioid misuse. Using a multi-province population-based cohort study, we estimate the impact of federal safety alerts on annual rates of codeine use in the Canadian pediatric population. We analyzed data from 8,156,948 children/adolescents in five Canadian provinces between 1996 and 2021, using a common protocol. Children/adolescents were categorized as: ≤ 12 years (children) or > 12 years (adolescents). We defined codeine exposure by ≥ 1 prescription filled for codeine alone or combined with other medications. For both age categories, we obtained province-specific codeine prescription filling rates per calendar year by dividing the number of children/adolescents with ≥ 1 codeine prescription filled by the number of person-time. Annual rates of codeine use per 1000 persons vary by province from 3.0 (Quebec) to 10.1 (Manitoba) in children, and from 5.5 to 51.3 in adolescents. After the 2013 HC advisory, exposure decreased in all provinces (adjusted level change from - 0.6 to - 18.4%) in children and from - 2.1 to - 17.9% in adolescents after the 2016 advisory. Annual rates declined over time in all provinces, following HC safety alerts specific to each of the two age categories.
Identifiants
pubmed: 38438444
doi: 10.1038/s41598-024-55758-3
pii: 10.1038/s41598-024-55758-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5370Informations de copyright
© 2024. The Author(s).
Références
Bell, J. et al. Prescription opioid dispensing in Australian children and adolescents: A national population-based study. Lancet Child Adolesc. Health 3(12), 881–888 (2019).
doi: 10.1016/S2352-4642(19)30329-3
pubmed: 31604614
Chidambaran, V., Sadhasivam, S. & Mahmoud, M. Codeine and opioid metabolism: Implications and alternatives for pediatric pain management. Curr. Opin. Anaesthesiol. 30(3), 349–356 (2017).
doi: 10.1097/ACO.0000000000000455
pubmed: 28323671
pmcid: 5482206
Choufi, S. et al. Opioid analgesic prescription in french children: A national population-based study. Int. J. Environ. Res. Public Health 18(24), 13316 (2021).
doi: 10.3390/ijerph182413316
pubmed: 34948923
pmcid: 8702064
Chua, K. P., Shrime, M. G. & Conti, R. M. Effect of FDA investigation on opioid prescribing to children after tonsillectomy/adenoidectomy. Pediatrics 140(6) (2017).
Hamina, A. et al. Filled prescriptions for opioids among children and adolescents - A nationwide study from 2010 to 2018. Acta Anaesthesiol. Scand. 65(10), 1475–1483 (2021).
doi: 10.1111/aas.13968
pubmed: 34374072
Kaiser, S. V. et al. National patterns of codeine prescriptions for children in the emergency department. Pediatrics 133(5), e1139–e1147 (2014).
doi: 10.1542/peds.2013-3171
pubmed: 24753533
pmcid: 4006438
Livingstone, M. J. et al. Codeine use among children in the United States: A nationally representative study from 1996 to 2013. Paediatr. Anaesth. 27(1), 19–27 (2017).
doi: 10.1111/pan.13033
pubmed: 27779367
Mathew, E., Kim, E. & Zempsky, W. Pharmacologic treatment of pain. Semin. Pediatr. Neurol. 23(3), 209–219 (2016).
doi: 10.1016/j.spen.2016.10.004
pubmed: 27989328
Rosen, D. M., Alcock, M. M. & Palmer, G. M. Opioids for acute pain management in children. Anaesth. Intens. Care 50(1–2), 81–94 (2022).
doi: 10.1177/0310057X211065769
Goldsobel, A. B. & Chipps, B. E. Cough in the pediatric population. J. Pediatr. 156(3), 352–358 (2010).
doi: 10.1016/j.jpeds.2009.12.004
pubmed: 20176183
Chua, K. P. & Conti, R. M. Prescriptions for codeine or hydrocodone cough and cold medications to US children and adolescents following US food and drug administration safety communications. JAMA Netw. Open. 4(11), e2134142 (2021).
doi: 10.1001/jamanetworkopen.2021.34142
pubmed: 34762115
pmcid: 8586901
Eccles, R. Codeine, cough and upper respiratory infection. Pulm Pharmacol. 9(5–6), 293–297 (1996).
doi: 10.1006/pulp.1996.0038
pubmed: 9232666
Horton, D. B., Gerhard, T. & Strom, B. L. Trends in cough and cold medicine recommendations for children in the United States, 2002–2015. JAMA Pediatr. 173(9), 885–887 (2019).
doi: 10.1001/jamapediatrics.2019.2252
pubmed: 31355863
Schroeder, K. & Fahey, T. Systematic review of randomised controlled trials of over the counter cough medicines for acute cough in adults. BMJ 324(7333), 329–331 (2002).
doi: 10.1136/bmj.324.7333.329
pubmed: 11834560
pmcid: 65295
Sloan, V. S. et al. A benefit risk review of pediatric use of hydrocodone/chlorpheniramine, a prescription opioid antitussive agent for the treatment of cough. Drugs Real World Outcomes 6(2), 47–57 (2019).
doi: 10.1007/s40801-019-0152-6
pubmed: 31073977
pmcid: 6520422
Takahama, K. & Shirasaki, T. Central and peripheral mechanisms of narcotic antitussives: Codeine-sensitive and -resistant coughs. Cough 3, 8 (2007).
doi: 10.1186/1745-9974-3-8
pubmed: 17620111
pmcid: 1950526
Bolser, D. C. & Davenport, P. W. Codeine and cough: An ineffective gold standard. Curr. Opin. Allergy Clin. Immunol. 7(1), 32–36 (2007).
doi: 10.1097/ACI.0b013e3280115145
pubmed: 17218808
pmcid: 2921574
Freestone, C. & Eccles, R. Assessment of the antitussive efficacy of codeine in cough associated with common cold. J. Pharm. Pharmacol. 49(10), 1045–1049 (1997).
doi: 10.1111/j.2042-7158.1997.tb06039.x
pubmed: 9364418
Taylor, J. A. et al. Efficacy of cough suppressants in children. J. Pediatr. 122(5 Pt 1), 799–802 (1993).
doi: 10.1016/S0022-3476(06)80031-4
pubmed: 8496765
Tremlett, M., Anderson, B. J. & Wolf, A. Pro-con debate: Is codeine a drug that still has a useful role in pediatric practice?. Paediatr. Anaesth. 20(2), 183–194 (2010).
doi: 10.1111/j.1460-9592.2009.03234.x
pubmed: 20059720
Eccles, R., Morris, S. & Jawad, M. Lack of effect of codeine in the treatment of cough associated with acute upper respiratory tract infection. J. Clin. Pharm. Ther. 17(3), 175–180 (1992).
doi: 10.1111/j.1365-2710.1992.tb01289.x
pubmed: 1639879
Health Canada. Use of codeine products by nursing mothers. October 8, 2008. Available from: https://www.canada.ca/en/news/archive/2008/10/use-codeine-products-nursing-mothers.html .
Health Canada. Health Canada’s review recommends codeine only be used in patients age 12 and older. Information update June 6, 2013. Available from: https://recalls-rappels.canada.ca/en/alert-recall/health-canada-s-review-recommends-codeine-only-be-used-patients-aged-12-and-over .
Health Canada. New safety measures for prescription codeine and hydrocodone to further restrict use in children and adolescents. July 28 2016. Available from: https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2016/59584a-eng.php?utm_source=twitter_hc&utm_medium=social_en&utm_content=july28_cod&utm_campaign=social_media_16 .
Goldman, J. L., Ziegler, C. & Burckardt, E. M. Otolaryngology practice patterns in pediatric tonsillectomy: The impact of the codeine boxed warning. Laryngoscope 128(1), 264–268 (2018).
doi: 10.1002/lary.26719
pubmed: 28608417
Canadian Institute for Health Information. Opioid Prescribing in Canada. In: How are Practices Changing? (CIHI, 2019).
Campbell, D. J. T. et al. Comparison of Canadian public medication insurance plans and the impact on out-of-pocket costs. CMAJ Open 5(4), E808–E813 (2017).
doi: 10.9778/cmajo.20170065
pubmed: 29180377
pmcid: 5741433
Morgan, S. G. et al. Estimated cost of universal public coverage of prescription drugs in Canada. CMAJ. 187(7), 491–497 (2015).
doi: 10.1503/cmaj.141564
pubmed: 25780047
pmcid: 4401594
Mahic, M. et al. Use of prescribed opioids by children and adolescents: Differences between Denmark Norway and Sweden. Eur. J. Pain. 19(8), 1095–1100 (2015).
doi: 10.1002/ejp.632
pubmed: 25410553
Carmona, J. et al. Prevalence and health characteristics of prescription opioid use, misuse, and use disorders among U.S. adolescents. J. Adolesc. Health. 66(5), 536–44 (2020).
doi: 10.1016/j.jadohealth.2019.11.306
pubmed: 31964613
pmcid: 7359040
Ramsey, L. B. et al. Prescribing prevalence of medications with potential genotype-guided dosing in pediatric patients. JAMA Netw. Open. 3(12), e2029411 (2020).
doi: 10.1001/jamanetworkopen.2020.29411
pubmed: 33315113
pmcid: 7737091
Tamblyn, R. et al. The use of prescription claims databases in pharmacoepidemiological research: The accuracy and comprehensiveness of the prescription claims database in Quebec. J. Clin. Epidemiol. 48(8), 999–1009 (1995).
doi: 10.1016/0895-4356(94)00234-H
pubmed: 7775999
Zhao, J. P. et al. Can we rely on pharmacy claims databases to ascertain maternal use of medications during pregnancy?. Birth Defects Res. 109(6), 423–431 (2017).
doi: 10.1002/bdra.23604
pubmed: 28398706
Fortier, I. et al. Maelstrom research guidelines for rigorous retrospective data harmonization. Int. J. Epidemiol. 46(1), 103–105 (2017).
pubmed: 27272186
Bérard, A., Kaul, P., Eltonsy, S., et al. The Canadian Mother-Child cohort active surveillance initiative (CAMCCO): Comparisions between Quebec, Manitoba, Saskatchewan, and Alberta. (2022).
Barnieh, L. et al. A systematic review of cost-sharing strategies used within publicly-funded drug plans in member countries of the organisation for economic co-operation and development. PLoS ONE 9(3), e90434 (2014).
doi: 10.1371/journal.pone.0090434
pubmed: 24618721
pmcid: 3949707